Mutagen-mediated enhancement of HIV-1 replication in persistently infected cells

Virology

Volumn 424, Issue 2, 2012, Pages 147-153

  Sánchez Jiménez, Carmen ^a   Olivares, Isabel ^a   de Ávila Lucas, Ana Isabel ^b   Toledano, Víctor ^a   Gutiérrez Rivas, Mónica ^a   Lorenzo Redondo, Ramón ^a   Grande Pérez, Ana ^c   Domingo, Esteban ^b,d   López Galíndez, Cecilio ^a  

^a INSTITUTO DE SALUD CARLOS III   (Spain)

^b CENTRO DE BIOLOGÍA MOLECULAR SEVERO OCHOA   (Spain)

^c UNIVERSITY OF MÁLAGA   (Spain)

^d INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

2 ',2 ' difluoro 2 ' deoxycytidine (gemcitabine); 5 fluorouracil (5 FU); 5 hydroxy 2 ' deoxycytidine (5 OHdC); HIV 1; HIV 1 persistent cell line; Lethal mutagenesis; Nucleoside analogs; Viral replication

Indexed keywords

5 HYDROXY 2' DEOXYCYTIDINE; ANTIVIRUS AGENT; FLUOROURACIL; GAG PROTEIN; GEMCITABINE; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ARTICLE; CELL VIABILITY; CONTROLLED STUDY; CPG ISLAND; CYTOKINE PRODUCTION; DRUG EFFICACY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; LONG TERMINAL REPEAT; LYMPHOID CELL LINE; METHYLATION; MUTAGENESIS; PRIORITY JOURNAL; PROCESS OPTIMIZATION; PROTEIN EXPRESSION; VIRUS INFECTIVITY; VIRUS REPLICATION;

CELL LINE; DEOXYCYTIDINE; FLUOROURACIL; HIV INFECTIONS; HIV-1; HUMANS; MUTAGENS; MUTATION; MUTATION RATE; RNA, VIRAL; VIRUS REPLICATION;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 84857032188     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2011.12.016     Document Type: Article

References (45)

1. Agudo R., Arias A., Pariente N., Perales C., Escarmis C., Jorge A., Marina A., Domingo E. Molecular characterization of a dual inhibitory and mutagenic activity of 5-fluorouridine triphosphate on viral RNA synthesis. Implications for lethal mutagenesis. J. Mol. Biol. 2008, 382(3):652-666.
2. Agudo R., Ferrer-Orta C., Arias A., de la Higuera I., Perales C., Perez-Luque R., Verdaguer N., Domingo E. A multi-step process of viral adaptation to a mutagenic nucleoside analogue by modulation of transition types leads to extinction-escape. PLoS Pathog. 2010, 6(8):e1001072.
3. Anderson J.P., Daifuku R., Loeb L.A. Viral error catastrophe by mutagenic nucleosides. Annu. Rev. Microbiol. 2004, 58:183-205.
4. Beumer J.H., Eiseman J.L., Parise R.A., Joseph E., Holleran J.L., Covey J.M., Egorin M.J. Pharmacokinetics, metabolism, and oral bioavailability of the DNA methyltransferase inhibitor 5-fluoro-2'-deoxycytidine in mice. Clin. Cancer Res. 2006, 12(24):7483-7491.
5. Blazkova J., Trejbalova K., Gondois-Rey F., Halfon P., Philibert P., Guiguen A., Verdin E., Olive D., Van Lint C., Hejnar J., Hirsch I. CpG methylation controls reactivation of HIV from latency. PLoS Pathog. 2009, 5(8):e1000554.
6. Burris H.A., Moore M.J., Andersen J., Green M.R., Rothenberg M.L., Modiano M.R., Cripps M.C., Portenoy R.K., Storniolo A.M., Tarassoff P., Nelson R., Dorr F.A., Stephens C.D., Von Hoff D.D. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J. Clin. Oncol. 1997, 15(6):2403-2413.
7. Chun T.W., Carruth L., Finzi D., Shen X., DiGiuseppe J.A., Taylor H., Hermankova M., Chadwick K., Margolick J., Quinn T.C., Kuo Y.H., Brookmeyer R., Zeiger M.A., Barditch-Crovo P., Siliciano R.F. Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature 1997, 387(6629):183-188.
8. Clouser C.L., Patterson S.E., Mansky L.M. Exploiting drug repositioning for discovery of a novel HIV combination therapy. J. Virol. 2010, 84(18):9301-9309.
9. Clouser C.L., Holtz C.M., Mullett M., Crankshaw D.L., Briggs J.E., Chauhan J., VanHoutan I.M., Patterson S.E., Mansky L.M. Analysis of the ex vivo and in vivo antiretroviral activity of gemcitabine. PLoS One 2011, 6(1):e15840.
10. Coiras M., Lopez-Huertas M.R., Mateos E., Alcami J. Caspase-3-mediated cleavage of p65/RelA results in a carboxy-terminal fragment that inhibits IkappaBalpha and enhances HIV-1 replication in human T lymphocytes. Retrovirology 2008, 5:109.
11. Coiras M., Lopez-Huertas M.R., Perez-Olmeda M., Alcami J. Understanding HIV-1 latency provides clues for the eradication of long-term reservoirs. Nat. Rev. Microbiol. 2009, 7(11):798-812.
12. Contreras A.M., Hiasa Y., He W., Terella A., Schmidt E.V., Chung R.T. Viral RNA mutations are region specific and increased by ribavirin in a full-length hepatitis C virus replication system. J. Virol. 2002, 76(17):8505-8517.
13. Crotty S., Cameron C.E., Andino R. RNA virus error catastrophe: direct molecular test by using ribavirin. Proc. Natl. Acad. Sci. U. S. A. 2001, 98(12):6895-6900.
14. Dapp M.J., Clouser C.L., Patterson S., Mansky L.M. 5-Azacytidine can induce lethal mutagenesis in human immunodeficiency virus type 1. J. Virol. 2009, 83(22):11950-11958.
15. Day C.W., Smee D.F., Julander J.G., Yamshchikov V.F., Sidwell R.W., Morrey J.D. Error-prone replication of West Nile virus caused by ribavirin. Antiviral Res. 2005, 67(1):38-45.
16. Derdeyn C.A., Decker J.M., Sfakianos J.N., Wu X., O'Brien W.A., Ratner L., Kappes J.C., Shaw G.M., Hunter E. Sensitivity of human immunodeficiency virus type 1 to the fusion inhibitor T-20 is modulated by coreceptor specificity defined by the V3 loop of gp120. J. Virol. 2000, 74(18):8358-8367.
17. Domingo E., Escarmis C., Lazaro E., Manrubia S.C. Quasispecies dynamics and RNA virus extinction. Virus Res. 2005, 107(2):129-139.
18. Eigen M. Error catastrophe and antiviral strategy. Proc. Natl. Acad. Sci. U. S. A. 2002, 99(21):13374-13376.
19. Finzi D., Hermankova M., Pierson T., Carruth L.M., Buck C., Chaisson R.E., Quinn T.C., Chadwick K., Margolick J., Brookmeyer R., Gallant J., Markowitz M., Ho D.D., Richman D.D., Siliciano R.F. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 1997, 278(5341):1295-1300.
20. Graci J.D., Cameron C.E. Therapeutically targeting RNA viruses via lethal mutagenesis. Future Virol. 2008, 3(6):553-566.
21. Grande-Perez A., Sierra S., Castro M.G., Domingo E., Lowenstein P.R. Molecular indetermination in the transition to error catastrophe: systematic elimination of lymphocytic choriomeningitis virus through mutagenesis does not correlate linearly with large increases in mutant spectrum complexity. Proc. Natl. Acad. Sci. U. S. A. 2002, 99(20):12938-12943.
22. Grande-Perez A., Gomez-Mariano G., Lowenstein P.R., Domingo E. Mutagenesis-induced, large fitness variations with an invariant arenavirus consensus genomic nucleotide sequence. J. Virol. 2005, 79(16):10451-10459.
23. Grande-Perez A., Lazaro E., Lowenstein P., Domingo E., Manrubia S.C. Suppression of viral infectivity through lethal defection. Proc. Natl. Acad. Sci. U. S. A. 2005, 102(12):4448-4452.
24. Harris K.S., Brabant W., Styrchak S., Gall A., Daifuku R. KP-1212/1461, a nucleoside designed for the treatment of HIV by viral mutagenesis. Antiviral Res. 2005, 67(1):1-9.
25. Holland J.J., Domingo E., de la Torre J.C., Steinhauer D.A. Mutation frequencies at defined single codon sites in vesicular stomatitis virus and poliovirus can be increased only slightly by chemical mutagenesis. J. Virol. 1990, 64(8):3960-3962.
26. Ishida T., Hamano A., Koiwa T., Watanabe T. 5' long terminal repeat (LTR)-selective methylation of latently infected HIV-1 provirus that is demethylated by reactivation signals. Retrovirology 2006, 3:69.
27. Larder B.A., Kemp S.D. Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT). Science 1989, 246(4934):1155-1158.
28. Leone G., Voso M.T., Teofili L., Lubbert M. Inhibitors of DNA methylation in the treatment of hematological malignancies and MDS. Clin. Immunol. 2003, 109(1):89-102.
29. Loeb L.A., Essigmann J.M., Kazazi F., Zhang J., Rose K.D., Mullins J.I. Lethal mutagenesis of HIV with mutagenic nucleoside analogs. Proc. Natl. Acad. Sci. U. S. A. 1999, 96(4):1492-1497.
30. Mullins J.I., Heath L., Hughes J.P., Kicha J., Styrchak S., Wong K.G., Rao U., Hansen A., Harris K.S., Laurent J.P., Li D., Simpson J.H., Essigmann J.M., Loeb L.A., Parkins J. Mutation of HIV-1 genomes in a clinical population treated with the mutagenic nucleoside KP1461. PLoS One 2011, 6(1):e15135.
31. Perales C., Agudo R., Domingo E. Counteracting quasispecies adaptability: extinction of a ribavirin-resistant virus mutant by an alternative mutagenic treatment. PLoS One 2009, 4(5):e5554.
32. Pogolotti A.L., Santi D.V. High-pressure liquid chromatography-ultraviolet analysis of intracellular nucleotides. Anal. Biochem. 1982, 126(2):335-345.
33. Ratner L., Haseltine W., Patarca R., Livak K.J., Starcich B., Josephs S.F., Doran E.R., Rafalski J.A., Whitehorn E.A., Baumeister K., et al. Complete nucleotide sequence of the AIDS virus, HTLV-III. Nature 1985, 313(6000):277-284.
34. Ruiz-Jarabo C.M., Ly C., Domingo E., de la Torre J.C. Lethal mutagenesis of the prototypic arenavirus lymphocytic choriomeningitis virus (LCMV). Virology 2003, 308(1):37-47.
35. Sanchez-Merino V., Munoz L., Perez-Pastrana M.E., Herrera M.I., Olivares I., Lopez-Galindez C. Genetic changes associated with distinct patterns of HIV type 1 persistence in chronically infected cell lines. AIDS Res. Hum. Retroviruses 2007, 23(2):251-260.
36. Sanchez-Palomino S., Rojas J.M., Martinez M.A., Fenyo E.M., Najera R., Domingo E., Lopez-Galindez C. Dilute passage promotes expression of genetic and phenotypic variants of human immunodeficiency virus type 1 in cell culture. J. Virol. 1993, 67(5):2938-2943.
37. Severson W.E., Schmaljohn C.S., Javadian A., Jonsson C.B. Ribavirin causes error catastrophe during Hantaan virus replication. J. Virol. 2003, 77(1):481-488.
38. Shafer R.W., Rhee S.Y., Pillay D., Miller V., Sandstrom P., Schapiro J.M., Kuritzkes D.R., Bennett D. HIV-1 protease and reverse transcriptase mutations for drug resistance surveillance. AIDS 2007, 21(2):215-223.
39. Sierra S., Davila M., Lowenstein P.R., Domingo E. Response of foot-and-mouth disease virus to increased mutagenesis: influence of viral load and fitness in loss of infectivity. J. Virol. 2000, 74(18):8316-8323.
40. Sierra M., Airaksinen A., Gonzalez-Lopez C., Agudo R., Arias A., Domingo E. Foot-and-mouth disease virus mutant with decreased sensitivity to ribavirin: implications for error catastrophe. J. Virol. 2007, 81(4):2012-2024.
41. Siliciano J.D., Kajdas J., Finzi D., Quinn T.C., Chadwick K., Margolick J.B., Kovacs C., Gange S.J., Siliciano R.F. Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells. Nat. Med. 2003, 9(6):727-728.
42. Streeter D.G., Witkowski J.T., Khare G.P., Sidwell R.W., Bauer R.J., Robins R.K., Simon L.N. Mechanism of action of 1-β-D-ribofuranosyl-1,2,4-triazole-3-carboxamide (Virazole), a new broad-spectrum antiviral agent. Proc. Natl. Acad. Sci. U. S. A. 1973, 70(4):1174-1178.
43. Tapia N., Fernandez G., Parera M., Gomez-Mariano G., Clotet B., Quinones-Mateu M., Domingo E., Martinez M.A. Combination of a mutagenic agent with a reverse transcriptase inhibitor results in systematic inhibition of HIV-1 infection. Virology 2005, 338(1):1-8.
44. Witte V., Laffert B., Gintschel P., Krautkramer E., Blume K., Fackler O.T., Baur A.S. Induction of HIV transcription by Nef involves Lck activation and protein kinase C theta raft recruitment leading to activation of ERK1/2 but not NF kappa B. J. Immunol. 2008, 181(12):8425-8432.
45. Zimmerman T.P., Wolberg G., Duncan G.S. Inhibition of lymphocyte-mediated cytolysis by 3-deazaadenosine: evidence for a methylation reaction essential to cytolysis. Proc. Natl. Acad. Sci. U. S. A. 1978, 75(12):6220-6224.